FDA approves label update of GLP-1RA as first-line option for T2DM

The FDA has approved a label update for semaglutide. This approval allows use of semaglutide as a first-line treatment option for adults with T2DM who have not previously taken diabetes medication.

Semaglutide – a GLP-1RA in pill form - was approved by the FDA in 2019 and is indicated along with diet and exercise to improve glycemic control for adults with T2DM.

“By taking semaglutide first, people with type 2 diabetes, in conjunction with their care teams, are now able to utilize this medicine early in their diabetes treatment journeys,” said Dr. Aaron King, Family Medicine and Diabetes Specialist.

Source: press release Novo Nordisk, Jan 13, 2023